Summit Therapeutics (SMMT) Competitors $22.12 -0.94 (-4.08%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$22.28 +0.15 (+0.70%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SMMT vs. TAK, ARGX, BNTX, ONC, TEVA, GMAB, ITCI, VTRS, MRNA, and RDYShould you be buying Summit Therapeutics stock or one of its competitors? The main competitors of Summit Therapeutics include Takeda Pharmaceutical (TAK), argenx (ARGX), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Moderna (MRNA), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Summit Therapeutics vs. Takeda Pharmaceutical argenx BioNTech Beigene Teva Pharmaceutical Industries Genmab A/S Intra-Cellular Therapies Viatris Moderna Dr. Reddy's Laboratories Takeda Pharmaceutical (NYSE:TAK) and Summit Therapeutics (NASDAQ:SMMT) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, community ranking, valuation, institutional ownership, analyst recommendations and media sentiment. Does the media prefer TAK or SMMT? In the previous week, Takeda Pharmaceutical had 1 more articles in the media than Summit Therapeutics. MarketBeat recorded 4 mentions for Takeda Pharmaceutical and 3 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.48 beat Takeda Pharmaceutical's score of 0.26 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer TAK or SMMT? Summit Therapeutics has a consensus price target of $33.57, suggesting a potential upside of 51.77%. Given Summit Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Summit Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86 Do institutionals and insiders hold more shares of TAK or SMMT? 9.2% of Takeda Pharmaceutical shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 0.0% of Takeda Pharmaceutical shares are held by insiders. Comparatively, 88.3% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community prefer TAK or SMMT? Summit Therapeutics received 203 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 58.38% of users gave Summit Therapeutics an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformTakeda PharmaceuticalOutperform Votes10056.82% Underperform Votes7643.18% Summit TherapeuticsOutperform Votes30358.38% Underperform Votes21641.62% Which has higher valuation & earnings, TAK or SMMT? Takeda Pharmaceutical has higher revenue and earnings than Summit Therapeutics. Summit Therapeutics is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$28.20B1.59$994.06M$0.4035.19Summit Therapeutics$700K23,303.42-$614.93M-$0.28-79.00 Which has more risk & volatility, TAK or SMMT? Takeda Pharmaceutical has a beta of 0.51, meaning that its share price is 49% less volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -0.88, meaning that its share price is 188% less volatile than the S&P 500. Is TAK or SMMT more profitable? Takeda Pharmaceutical has a net margin of 4.53% compared to Summit Therapeutics' net margin of 0.00%. Takeda Pharmaceutical's return on equity of 9.39% beat Summit Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical4.53% 9.39% 4.53% Summit Therapeutics N/A -85.42%-52.66% SummaryTakeda Pharmaceutical beats Summit Therapeutics on 10 of the 18 factors compared between the two stocks. Get Summit Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SMMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SMMT vs. The Competition Export to ExcelMetricSummit TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.01B$7.07B$5.84B$9.15BDividend YieldN/A2.75%4.75%3.85%P/E Ratio-79.005.4725.4719.00Price / Sales23,303.42306.08447.5876.30Price / CashN/A65.6738.0134.83Price / Book201.096.717.644.62Net Income-$614.93M$138.33M$3.18B$245.85M7 Day Performance3.51%-2.61%-1.99%-2.68%1 Month Performance-5.95%-2.32%-0.42%-2.19%1 Year Performance414.42%-5.31%16.51%12.84% Summit Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SMMTSummit Therapeutics2.3117 of 5 stars$22.12-4.1%$33.57+51.8%+438.2%$17.01B$700,000.00-79.00110Gap UpTAKTakeda Pharmaceutical2.335 of 5 stars$13.54-0.6%N/A-4.4%$43.07B$28.20B33.8449,281Positive NewsARGXargenx2.5004 of 5 stars$639.41-1.8%$658.39+3.0%+61.1%$38.85B$1.27B-726.601,148News CoveragePositive NewsBNTXBioNTech2.4325 of 5 stars$119.83-2.4%$142.72+19.1%+29.4%$28.73B$4.13B-57.066,133Positive NewsONCBeigeneN/A$230.86+2.4%N/AN/A$22.56B$2.46B-28.0210,600Insider TradeNews CoverageGap UpTEVATeva Pharmaceutical Industries2.8895 of 5 stars$16.24-2.4%$23.57+45.2%+28.8%$18.39B$16.54B-11.2037,851GMABGenmab A/S4.5905 of 5 stars$21.30+1.8%$42.17+98.0%-22.8%$14.10B$2.39B20.682,204ITCIIntra-Cellular Therapies3.8866 of 5 stars$127.82-0.2%$103.62-18.9%+75.5%$13.59B$464.37M-146.92560Earnings ReportAnalyst ForecastNews CoverageVTRSViatris2.0155 of 5 stars$10.80flat$13.67+26.5%-15.2%$12.89B$15.43B-14.5938,000News CoverageMRNAModerna4.7351 of 5 stars$32.99+3.4%$66.89+102.8%-59.4%$12.70B$6.85B-5.675,600Analyst DowngradeOptions VolumeHigh Trading VolumeRDYDr. Reddy's Laboratories3.0362 of 5 stars$13.60-2.8%$17.00+25.0%-11.9%$11.35B$311.31B21.6527,048 Related Companies and Tools Related Companies Takeda Pharmaceutical Competitors argenx Competitors BioNTech Competitors Beigene Competitors Teva Pharmaceutical Industries Competitors Genmab A/S Competitors Intra-Cellular Therapies Competitors Viatris Competitors Moderna Competitors Dr. Reddy's Laboratories Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SMMT) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
